Wedbush Reiterates Outperform on Fate Therapeutics, Maintains $7 Price Target

Benzinga · 4d ago
Wedbush analyst Martin Fan reiterates Fate Therapeutics (NASDAQ:FATE) with a Outperform and maintains $7 price target.